Previous close | 59.70 |
Open | 61.56 |
Bid | 62.00 x 1300 |
Ask | 62.40 x 1300 |
Day's range | 60.28 - 63.80 |
52-week range | 58.93 - 96.12 |
Volume | |
Avg. volume | 3,667,435 |
Market cap | 37.584B |
Beta (5Y monthly) | 1.11 |
PE ratio (TTM) | 26.10 |
EPS (TTM) | 2.39 |
Earnings date | 23 Oct 2024 - 28 Oct 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 82.05 |
FEATURE Shares of Edwards Lifesciences fell sharply after the medical-technologies company’s quarterly earnings report and guidance left investors disappointed. For its second quarter, ended June 30, the company reported adjusted earnings per share of 70 cents, beating Wall Street’s forecast by a penny, according to FactSet.
Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.
While the top- and bottom-line numbers for Edwards Lifesciences (EW) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.